To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. 1. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc. 2. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI 3. Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke) 4. Factors which may affect safety or efficacy of ticagrelor
Study Type
OBSERVATIONAL
Enrollment
663
Research Site
Aichi, Japan
Research Site
Aichi, Japan
Research Site
Aichi, Japan
Research Site
Akita, Japan
Research Site
Chiba, Japan
Research Site
Chiba, Japan
Research Site
Fukuoka, Japan
Research Site
Fukuoka, Japan
Research Site
Fukuoka, Japan
Research Site
Fukuoka, Japan
...and 61 more locations
Adverse event incidence
Time frame: from baseline to 4 years
Incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI
Time frame: from baseline to 4 years
Incidence of cardiovascular events
Time frame: from baseline to 4 years
Factors which may affect incidence of bleeding, dyspnoea, bradyarrhythmia, analysed by patient demographic characteristic and by treatment
Time frame: from baseline to 4 years
Factors which may affect incidence of cardiovascular events, analysed by patient demographic characteristic and by treatment
Time frame: from baseline to 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.